Radiation Induced Oral MucositisPhase 2NCT07020754
Effect of Arginine- and Glutamine-based Oral Formulations on Salivary Biomarkers and Clinical Severity of Radiation-induced Oral Mucositis in Head and Neck Cancer: A Randomized Controlled Trial
A Phase 2 study testing L-arginine Oral Suspension and L-glutamine Oral Suspension in people with Radiation Induced Oral Mucositis and Oral Mucositis, run by Ain Shams University at 1 site in Egypt.
Trial summary
This triple-blinded, randomized controlled clinical trial investigates the effectiveness of L-arginine and L-glutamine oral suspensions in managing radiation-induced oral mucositis (RIOM) in patients with head and neck cancer (HNC) undergoing radiotherapy. Read more about this study
- Who is it for?
- Ages 20 to 70 years
- Conditions the study is for
- Radiation Induced Oral Mucositis, Oral Mucositis, Oral Mucositis Due to Radiation
- What is being tested?
- L-arginine Oral Suspension and L-glutamine Oral Suspension
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 84 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Apr 2025to 25 Jan 2026
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age between 20 and 70 years
- Diagnosed with head and neck cancer (HNC) and undergoing radiotherapy (RT)
- Development of oral mucositis during the 2nd to 3rd week of RT
- Receiving a minimum radiation dose of 50 Gy to the oral cavity
- Undergoing intensity-modulated radiotherapy (IMRT) with three-dimensional conformal techniques after complete tumor resection
- Ability and willingness to provide informed consent
- Able to comply with study procedures and follow-up assessments
Who cannot join
- History of prior radiotherapy
- Diagnosed with diabetes mellitus
- Presence of salivary gland tumors
- Renal or hepatic insufficiency
- Sepsis or any active systemic infection
- Distant metastases
- Any condition that may interfere with oral sample collection or affect EGF levels (e.g., autoimmune oral disease)
Trial locations and contacts
1 site in 1 country.
Egypt1 site
Faculty of Dentistry, Future University in Egypt
Cairo, Cairo Governorate, 10226
About this study
This triple-blinded, randomized controlled clinical trial investigates the effectiveness of L-arginine and L-glutamine oral suspensions in managing radiation-induced oral mucositis (RIOM) in patients with head and neck cancer (HNC) undergoing radiotherapy. A total of 69 patients are randomly assigned to three groups: L-arginine + maltodextrin, glutamine + maltodextrin, or maltodextrin alone (control).
The interventions are administered as a swish-and-swallow solution three times daily from the second to seventh week of radiotherapy. Key outcomes assessed include oral mucositis severity (WHO scale), pain intensity (VAS), body mass index (BMI), oral health-related quality of life (OHIP-14), and salivary epidermal growth factor (EGF) levels. The study aims to determine whether L-arginine offers superior mucosal healing and symptom relief compared to glutamine or placebo.
Read the detailed description
Radiation-induced oral mucositis (RIOM) is recognized as a frequent and severe complication among patients with head and neck cancer (HNC) who undergo radiotherapy (RT) 1. It manifests as damage to healthy tissues, specifically inflammation and/or ulceration of the oral mucosa, affecting over 80% of these patients receiving radiation therapy 2.
RIOM manifests as a normal tissue injury lasting from 7 to 98 days, initiated by acute inflammation in the oral mucosa, tongue, and pharynx following RT exposure 1. This inflammation is accompanied by the accumulation of various inflammatory cells and the secretion of cytokines, chemotactic agents, and growth factors. RIOM may escalate into a life-threatening condition due to significant blockages that restrict the intake of food and water, leading to weight loss and septic issues from the loss of protective epithelial and basement membrane layers. Consequently, these complications can disrupt cancer treatment and necessitate changes in the radiation dose, thus impacting local tumor control.3 The pathogenesis of RIOM associated with RT for HNC unfolds through a complex, multi-stage process. Initially, ionizing radiation directly damages cellular DNA within the radiation field, resulting in lethal double-strand breaks. When these breaks are not repaired accurately, it leads to programmed cell death or apoptosis. Concurrently, this radiation exposure stimulates various cells such as endothelial cells and fibroblasts to produce reactive oxygen species (ROS). These ROS further exacerbate DNA damage and disrupt cellular functions by modifying protein and lipid membrane structures, leading to escalated inflammation 4.
When excessive ROS accumulate, they cause oxidative stress, managed by antioxidants like superoxide dismutase and glutathione peroxidase. Disruptions in this balance lead to oxidative damage, increasing the risk of cancer and inflammatory conditions. Chemoradiation activates NF-kappa B, heightening pro-inflammatory cytokine levels that drive the progression to mucosal ulceration characteristic of OM. This condition severely impacts patients' nutrition and oral hygiene and increases the risk of secondary infections due to deeper tissue damage 5.
L- glutamine is L-alpha-amino acid. It is the most abundant free amino acid in human blood. L- glutamine is needed for several functions in the body including for the synthesis of proteins as well as an energy source. L-glutamine can be synthesized by the body and can also be obtained from the diet if needed.6 L- glutamine is crucial for powering lymphocytes and the gastrointestinal tract, helping to protect against infections and maintaining the mucosal barrier. It's important in cellular metabolism and acts as a nitrogen carrier across various tissues. Although its plasma levels remain stable, glutamine is predominantly stored in muscles and regulated by the liver 7. Several studies indicated that glutamine could decrease both the frequency and intensity of OM 8-13.
L-arginine, a conditionally essential amino acid, is primarily metabolized by enzymes such as nitric oxide synthase (NOS), arginine decarboxylase, and arginase (ARG), contributing to the synthesis of proteins and various bioactive molecules like nitric oxide (NO), proline, creatine, and polyamines 14. There is growing interest in enhancing the physiological roles of arginine, particularly in reducing intestinal inflammation and oxidative stress 15. Previous research has shown that L-arginine supplementation in both animals and humans with intestinal disorders can lessen intestinal damage, alleviate oxidative stress and inflammation, and help reestablish mucosal immune balance. Notably, Coburn et al. have documented that L-arginine supplementation reduced intestinal inflammation in mouse models of dextran sulfate sodium (DSS)- induced colitis, an experimental model of IBD.16 L-arginine significantly enhances wound healing through various mechanisms. It is crucial for collagen synthesis, which is fundamental for new tissue development and the formation of strong connective tissue. This amino acid also has anti-inflammatory effects that regulate the body's response to injury, reducing the risk of chronic inflammation that can impede healing. Additionally, l-arginine promotes fibroblast proliferation, which is essential for producing collagen and other extracellular matrix components that aid in wound repair. Indirect benefits of l-arginine include improved circulation and blood flow to the wound area, supplying necessary oxygen and nutrients, and bolstering the immune system to fight infections and support healing processes 17-20.
Based on the various physiological properties of L-arginine, its anti-inflammatory effects, and its capacity for wound healing and tissue repair, this study aim to evaluate the effect of L-arginine oral suspension versus glutamine oral suspension on salivary EGF, and on management of radiation-induced oral mucositis (RIOM) and its associated symptoms, as well as assessing their effects on the oral health related quality of life in HNC patients.
- Being tested
- L-arginine Oral Suspension, L-glutamine Oral Suspension, Maltodextrin Oral Suspension (Control)
- Keywords
- Radiation-induced oral mucositis (RIOM), Head and neck cancer (HNC), L-arginine, Epidermal growth factor (EGF), L-glutamine
- Medical subject headings
- Stomatitis, Head and Neck Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
L-arginine Oral SuspensionDietary supplement
Type: Dietary supplement
Dosage: 5 g L-arginine + 5 g maltodextrin
Route: Oral (swish-and-swallow)
Frequency: Three times daily, 30 minutes before meals
Duration: From the 2nd to the 7th week of radiotherapy
L-glutamine Oral SuspensionDietary supplement
Type: Dietary supplement
Dosage: 5 g L-glutamine + 5 g maltodextrin
Route: Oral (swish-and-swallow)
Frequency: Three times daily, 30 minutes before meals
Duration: From the 2nd to the 7th week of radiotherapy
Maltodextrin Oral Suspension (Control)Dietary supplement
Type: Placebo comparator
Dosage: 10 g maltodextrin
Route: Oral (swish-and-swallow)
Frequency: Three times daily, 30 minutes before meals
Duration: From the 2nd to the 7th week of radiotherapy
| Study group | Role | What they receive |
|---|---|---|
| Group I - L-arginine + Maltodextrin Oral Suspension | Experimental | Patients receive 5 g of L-arginine + 5 g of maltodextrin dissolved in cold distilled water. Receives: Dietary Supplement: L-arginine Oral Suspension |
| Group II - Glutamine + Maltodextrin Oral Suspension | Active comparator | Group II - Glutamine + Maltodextrin Oral Suspension Receives: Dietary Supplement: L-glutamine Oral Suspension |
| Group III - Maltodextrin Oral Suspension (Control Group) | Placebo comparator | Patients receive 10 g of maltodextrin only, prepared and administered identically to the other groups. Receives: Dietary Supplement: Maltodextrin Oral Suspension (Control) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in salivary IL-6 levels during radiotherapy-induced oral mucositis
Salivary interleukin-6 (IL-6) concentration will be measured using enzyme-linked immunosorbent assay (ELISA) to assess inflammatory response during radiotherapy. The primary endpoint is the between-group difference in IL-6 change from baseline to peak mucositis following arginine-, glutamine-, or maltodextrin-based oral intervention. IL-6 was selected as the primary biomarker due to its established role in radiation-induced oral mucosal inflammation and association with mucositis severity.
Measured: From week 2 of radiotherapy (baseline) , week 5 of radiotherapy (peak mucositis phase, week 7 of RT
Secondary outcomes (4)
Change in Salivary Epidermal Growth Factor (EGF) Levels
Description:
Measures the concentration of salivary EGF, a key biomarker involved in mucosal healing and epithelial regeneration. This outcome assesses whether L-arginine or L-glutamine can enhance EGF production, contributing to faster recovery from oral mucositis.
Method:
Whole saliva is collected under stimulation, processed, and analyzed using ELISA (Enzyme-Linked Immunosorbent Assay).
Measured: Baseline (2nd week of radiotherapy), week 5 of radiotherapy (peak mucositis phase) End of treatment (7th week)
Change in salivary nitric oxide levels during radiotherapy-induced oral mucositis
Salivary nitric oxide concentration, expressed as total nitrite/nitrate levels, will be quantified using a colorimetric assay to evaluate oxidative and inflammatory signaling during radiotherapy. The outcome measure is the between-group difference in nitric oxide change from baseline to peak mucositis and end of radiotherapy following arginine-, glutamine-, or maltodextrin-based oral intervention. Nitric oxide is included as a secondary biomarker due to its dual role in radiation-induced oxidative stress and mucosal wound healing.
Measured: From week 2 of radiotherapy (baseline) to week 5 (peak mucositis) and week 7 (end of radiotherapy)
Severity of Oral Mucositis
Assessed using the WHO Oral Toxicity Scale, which grades mucositis from 0 (no symptoms) to 4 (severe ulceration requiring feeding support). This measure reflects the extent of mucosal injury caused by radiotherapy and the potential protective effect of interventions.
Measured: 2nd, 5th, and 7th weeks of radiotherapy
Pain Intensity
Evaluated using the Visual Analogue Scale (VAS) ranging from 0 (no pain) to 10 (worst imaginable pain). This subjective measure tracks changes in patient-reported pain severity throughout treatment.
Measured: 2nd, 5th, and 7th weeks of radiotherapy
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jun 2025
- Study start1 Apr 2025
- Primary completion1 Jan 2026
- Study completion25 Jan 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Radiation Induced Oral MucositisStudies of the same condition, open and under way.
- More trials run by Ain Shams UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 84 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ain Shams University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Fatma ElSayed, Ain Shams University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07020754
- Sponsor's protocol ID
- FUE.REC25/8-2025
- Status last verified
- Jan 2026
- First submitted
- 6 Jun 2025
- Last updated
- 30 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Hassanein FEA, Ahmed DE, Elkot S, Abou-Bakr A. Nutritional Amino Acid Supplementation Reduces Severity and Enhances Recovery of Radiation-Induced Oral Mucositis: A Triple-Blind Randomized Clinical Trial. J Oral Rehabil. 2026 Jun 25. doi: 10.1111/joor.70246. Online ahead of print.
PubMed 42347702
Study at a glance
From the registry record, last updated by the sponsor on 30 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Arginine- and Glutamine-based Oral Formulations on Salivary Biomarkers and Clinical Severity of Radiation-induced Oral Mucositis in Head and Neck Cancer: A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07020754
- Acronym / sponsor ID
- FUE.REC25/8-2025
- Keywords
- Radiation-induced oral mucositis (RIOM), Head and neck cancer (HNC), L-arginine, Epidermal growth factor (EGF), L-glutamine
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 84 participants (actual)
- Lead sponsor
- Ain Shams UniversityUniversity, hospital or other
- Study start
- 1 Apr 2025 (actual)
- Primary completion
- 1 Jan 2026 (actual)
- Study completion
- 25 Jan 2026 (actual)
- First posted
- 13 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This triple-blinded, randomized controlled clinical trial investigates the effectiveness of L-arginine and L-glutamine oral suspensions in managing radiation-induced oral mucositis (RIOM) in patients with head and neck cancer (HNC) undergoing radiotherapy. A total of 69 patients are randomly assigned to three groups: L-arginine + maltodextrin, glutamine + maltodextrin, or maltodextrin alone (control).
The interventions are administered as a swish-and-swallow solution three times daily from the second to seventh week of radiotherapy. Key outcomes assessed include oral mucositis severity (WHO scale), pain intensity (VAS), body mass index (BMI), oral health-related quality of life (OHIP-14), and salivary epidermal growth factor (EGF) levels. The study aims to determine whether L-arginine offers superior mucosal healing and symptom relief compared to glutamine or placebo.
Detailed description
Radiation-induced oral mucositis (RIOM) is recognized as a frequent and severe complication among patients with head and neck cancer (HNC) who undergo radiotherapy (RT) 1. It manifests as damage to healthy tissues, specifically inflammation and/or ulceration of the oral mucosa, affecting over 80% of these patients receiving radiation therapy 2.
RIOM manifests as a normal tissue injury lasting from 7 to 98 days, initiated by acute inflammation in the oral mucosa, tongue, and pharynx following RT exposure 1. This inflammation is accompanied by the accumulation of various inflammatory cells and the secretion of cytokines, chemotactic agents, and growth factors. RIOM may escalate into a life-threatening condition due to significant blockages that restrict the intake of food and water, leading to weight loss and septic issues from the loss of protective epithelial and basement membrane layers. Consequently, these complications can disrupt cancer treatment and necessitate changes in the radiation dose, thus impacting local tumor control.3 The pathogenesis of RIOM associated with RT for HNC unfolds through a complex, multi-stage process. Initially, ionizing radiation directly damages cellular DNA within the radiation field, resulting in lethal double-strand breaks. When these breaks are not repaired accurately, it leads to programmed cell death or apoptosis. Concurrently, this radiation exposure stimulates various cells such as endothelial cells and fibroblasts to produce reactive oxygen species (ROS). These ROS further exacerbate DNA damage and disrupt cellular functions by modifying protein and lipid membrane structures, leading to escalated inflammation 4.
When excessive ROS accumulate, they cause oxidative stress, managed by antioxidants like superoxide dismutase and glutathione peroxidase. Disruptions in this balance lead to oxidative damage, increasing the risk of cancer and inflammatory conditions. Chemoradiation activates NF-kappa B, heightening pro-inflammatory cytokine levels that drive the progression to mucosal ulceration characteristic of OM. This condition severely impacts patients' nutrition and oral hygiene and increases the risk of secondary infections due to deeper tissue damage 5.
L- glutamine is L-alpha-amino acid. It is the most abundant free amino acid in human blood. L- glutamine is needed for several functions in the body including for the synthesis of proteins as well as an energy source. L-glutamine can be synthesized by the body and can also be obtained from the diet if needed.6 L- glutamine is crucial for powering lymphocytes and the gastrointestinal tract, helping to protect against infections and maintaining the mucosal barrier. It's important in cellular metabolism and acts as a nitrogen carrier across various tissues. Although its plasma levels remain stable, glutamine is predominantly stored in muscles and regulated by the liver 7. Several studies indicated that glutamine could decrease both the frequency and intensity of OM 8-13.
L-arginine, a conditionally essential amino acid, is primarily metabolized by enzymes such as nitric oxide synthase (NOS), arginine decarboxylase, and arginase (ARG), contributing to the synthesis of proteins and various bioactive molecules like nitric oxide (NO), proline, creatine, and polyamines 14. There is growing interest in enhancing the physiological roles of arginine, particularly in reducing intestinal inflammation and oxidative stress 15. Previous research has shown that L-arginine supplementation in both animals and humans with intestinal disorders can lessen intestinal damage, alleviate oxidative stress and inflammation, and help reestablish mucosal immune balance. Notably, Coburn et al. have documented that L-arginine supplementation reduced intestinal inflammation in mouse models of dextran sulfate sodium (DSS)- induced colitis, an experimental model of IBD.16 L-arginine significantly enhances wound healing through various mechanisms. It is crucial for collagen synthesis, which is fundamental for new tissue development and the formation of strong connective tissue. This amino acid also has anti-inflammatory effects that regulate the body's response to injury, reducing the risk of chronic inflammation that can impede healing. Additionally, l-arginine promotes fibroblast proliferation, which is essential for producing collagen and other extracellular matrix components that aid in wound repair. Indirect benefits of l-arginine include improved circulation and blood flow to the wound area, supplying necessary oxygen and nutrients, and bolstering the immune system to fight infections and support healing processes 17-20.
Based on the various physiological properties of L-arginine, its anti-inflammatory effects, and its capacity for wound healing and tissue repair, this study aim to evaluate the effect of L-arginine oral suspension versus glutamine oral suspension on salivary EGF, and on management of radiation-induced oral mucositis (RIOM) and its associated symptoms, as well as assessing their effects on the oral health related quality of life in HNC patients.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Group I - L-arginine + Maltodextrin Oral Suspension | Experimental | Dietary Supplement: L-arginine Oral SuspensionPatients receive 5 g of L-arginine + 5 g of maltodextrin dissolved in cold distilled water. |
| Group II - Glutamine + Maltodextrin Oral Suspension | Active comparator | Dietary Supplement: L-glutamine Oral SuspensionGroup II - Glutamine + Maltodextrin Oral Suspension |
| Group III - Maltodextrin Oral Suspension (Control Group) | Placebo comparator | Dietary Supplement: Maltodextrin Oral Suspension (Control)Patients receive 10 g of maltodextrin only, prepared and administered identically to the other groups. |
Who may qualify
- Ages
- 20 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Age between 20 and 70 years
- Diagnosed with head and neck cancer (HNC) and undergoing radiotherapy (RT)
- Development of oral mucositis during the 2nd to 3rd week of RT
- Receiving a minimum radiation dose of 50 Gy to the oral cavity
- Undergoing intensity-modulated radiotherapy (IMRT) with three-dimensional conformal techniques after complete tumor resection
Key exclusion criteria (7 listed)
- History of prior radiotherapy
- Diagnosed with diabetes mellitus
- Presence of salivary gland tumors
- Renal or hepatic insufficiency
- Sepsis or any active systemic infection
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| L-arginine Oral SuspensionType: Dietary supplement Dosage: 5 g L-arginine + 5 g maltodextrin Route: Oral (swish-and-swallow) Frequency: Three times daily, 30 minutes before meals Duration: From the 2nd to the 7th week of radiotherapy | Dietary supplement | Group I - L-arginine + Maltodextrin Oral Suspension |
| L-glutamine Oral SuspensionType: Dietary supplement Dosage: 5 g L-glutamine + 5 g maltodextrin Route: Oral (swish-and-swallow) Frequency: Three times daily, 30 minutes before meals Duration: From the 2nd to the 7th week of radiotherapy | Dietary supplement | Group II - Glutamine + Maltodextrin Oral Suspension |
| Maltodextrin Oral Suspension (Control)Type: Placebo comparator Dosage: 10 g maltodextrin Route: Oral (swish-and-swallow) Frequency: Three times daily, 30 minutes before meals Duration: From the 2nd to the 7th week of radiotherapy | Dietary supplement | Group III - Maltodextrin Oral Suspension (Control Group) |
Primary outcome
Change in salivary IL-6 levels during radiotherapy-induced oral mucositis
Time frame: From week 2 of radiotherapy (baseline) , week 5 of radiotherapy (peak mucositis phase, week 7 of RT
Salivary interleukin-6 (IL-6) concentration will be measured using enzyme-linked immunosorbent assay (ELISA) to assess inflammatory response during radiotherapy. The primary endpoint is the between-group difference in IL-6 change from baseline to peak mucositis following arginine-, glutamine-, or maltodextrin-based oral intervention. IL-6 was selected as the primary biomarker due to its established role in radiation-induced oral mucosal inflammation and association with mucositis severity.
4 secondary outcomes
Change in Salivary Epidermal Growth Factor (EGF) Levels
Time frame: Baseline (2nd week of radiotherapy), week 5 of radiotherapy (peak mucositis phase) End of treatment (7th week)
Change in salivary nitric oxide levels during radiotherapy-induced oral mucositis
Time frame: From week 2 of radiotherapy (baseline) to week 5 (peak mucositis) and week 7 (end of radiotherapy)
Severity of Oral Mucositis
Time frame: 2nd, 5th, and 7th weeks of radiotherapy
Pain Intensity
Time frame: 2nd, 5th, and 7th weeks of radiotherapy
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jan 2026.
- Derived from this study: PubMed 42347702Hassanein FEA, Ahmed DE, Elkot S, Abou-Bakr A. Nutritional Amino Acid Supplementation Reduces Severity and Enhances Recovery of Radiation-Induced Oral Mucositis: A Triple-Blind Randomized Clinical Trial. J Oral Rehabil. 2026 Jun 25. doi: 10.1111/joor.70246. Online ahead of print.
- Individual participant dataSharing planned: Undecided
Related trials for Radiation Induced Oral Mucositis
RecruitingPhase 2
Traditional Chinese Medicine Preparation Alleviates Radiotherapy-induced Oral Mucositis in Head and Neck Cancer Patients.
Radiotherapy-induced Oral Mucositis
RecruitingPhase 2
Taurine for the Prevention and Treatment of Radiation-induced Oral Mucositis in Patients With Nasopharyngeal Carcinoma
Oral Mucositis (Ulcerative) Due to Radiation, Nasopharyngeal Carcinoma (NPC)
Active, not recruiting
Photobiomodulation for the Prevention of Radiation Induced Oral Mucositis
Mucositis Oral, Head and Neck Cancer
Enrolling by invitationPhase 1/2
Photobiomodulation Alone Versus Photobiomodulation Combined With Topical Oral Oxygen Therapy for Radiotherapy-Induced Oral Mucositis in Head and Neck Cancer Patients: A Randomized Clinical Trial
Mucositis Oral, Head & Neck Cancer
Not yet recruiting
Citrus Sinensis Peel Gel for Radiation-Induced Oral Mucositis
Radiation-induced Oral Mucositis, Head and Neck Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing L-arginine Oral Suspension and L-glutamine Oral Suspension in people with Radiation Induced Oral Mucositis and Oral Mucositis, run by Ain Shams University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in salivary IL-6 levels during radiotherapy-induced oral mucositis (time frame: From week 2 of radiotherapy (baseline) , week 5 of radiotherapy (peak mucositis phase, week 7 of RT). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07020754, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jan 2026.